Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jacobson

Showing results (1191-1200 of 1,226) with videos related to

Pageof 123
Sort By:
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Cell Host & Microbe|January 3, 2023
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapyXiaodong Lian, Kyra W Seiger, Elizabeth M Parsons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2024
Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite CohortMichalina Montaño, Adrienne E Shapiro, Bridget M Whitney, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1Tong-Ming Fu, Sheri A Dubey, Devan V Mehrotra, et al.
The American Journal of Gastroenterology|November 11, 2005
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis CIra M Jacobson, Stevan A Gonzalez, Furqaan Ahmed, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2023
HIV post-treatment controllers have distinct immunological and virological featuresBehzad Etemad, Xiaoming Sun, Yijia Li, et al.
Emerging Microbes & Infections|March 6, 2024
Effective and targeted latency reversal in CD4<sup>+</sup> T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infectionMinh Ha Ngo, Joshua Pankrac, Ryan C Y Ho, et al.
Science Translational Medicine|September 17, 2025
Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profilesToong Seng Tan, Ce Gao, Alexander S Hochroth, et al.
Open Forum Infectious Diseases|August 11, 2021
Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)Lisa R Metsch, Daniel J Feaster, Lauren K Gooden, et al.
Pageof 123

Showing results (1191-1200 of 1,226) with videos related to

Sort By:
Pageof 123
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Cell Host & Microbe|January 3, 2023
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapyXiaodong Lian, Kyra W Seiger, Elizabeth M Parsons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2024
Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite CohortMichalina Montaño, Adrienne E Shapiro, Bridget M Whitney, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Evaluation of cellular immune responses in subjects chronically infected with HIV type 1Tong-Ming Fu, Sheri A Dubey, Devan V Mehrotra, et al.
The American Journal of Gastroenterology|November 11, 2005
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis CIra M Jacobson, Stevan A Gonzalez, Furqaan Ahmed, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2023
HIV post-treatment controllers have distinct immunological and virological featuresBehzad Etemad, Xiaoming Sun, Yijia Li, et al.
Emerging Microbes & Infections|March 6, 2024
Effective and targeted latency reversal in CD4<sup>+</sup> T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infectionMinh Ha Ngo, Joshua Pankrac, Ryan C Y Ho, et al.
Science Translational Medicine|September 17, 2025
Sex differences in HIV-1 reservoir cell selection are linked to altered innate immune profilesToong Seng Tan, Ce Gao, Alexander S Hochroth, et al.
Open Forum Infectious Diseases|August 11, 2021
Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)Lisa R Metsch, Daniel J Feaster, Lauren K Gooden, et al.
Pageof 123